Novo Nordisk NVO announced Monday that its oral GLP-1 called Rybelsus wasn’t better than a placebo at delaying the progression of Alzheimer’s disease. It shared few details beyond saying the ...

C&EN networking event in New York City. Please join us if you’re in town! Here’s a link to the invitation. Questions? Comments? Tips? Let us know. Email Michael McCoy, C&EN’s executive editor for ...

Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in ...

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk's trials for Alzheimer's using the GLP-1 drug, Rybelsus, did not meet their primary goals but showed potential in preventing the disease. Experts believe further trials on people at risk, ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Novo Nordisk stock falls after disappointing results from Alzheimer's trial. Analysts remain cautious about future growth ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...

Novo Nordisk GLP-1 fails to slow Alzheimer's in phase 3 trials involving 3,808 adults with mild cognitive impairment or dementia.

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts ...